News
BCDA
0.9015
-2.12%
-0.0195
BioCardia announces FDA acceptance of Helix pre-submission package
TipRanks · 10/19 13:41
BioCardia Advances Helix Catheter Toward FDA Clearance
TipRanks · 10/19 13:38
Weekly Report: what happened at BCDA last week (1012-1016)?
Weekly Report · 10/19 09:49
Weekly Report: what happened at BCDA last week (1005-1009)?
Weekly Report · 10/12 09:52
BioCardia Advances CardiAMP HF II Heart Failure Trial
TipRanks · 10/07 13:33
Weekly Report: what happened at BCDA last week (0928-1002)?
Weekly Report · 10/05 09:51
BioCardia Submits Revised FDA De Novo for Helix
TipRanks · 10/01 13:50
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
Barchart · 10/01 08:15
Weekly Report: what happened at BCDA last week (0921-0925)?
Weekly Report · 09/28 09:48
BioCardia Advances Regulatory Milestones for Cardiovascular Therapies
TipRanks · 09/23 13:51
BioCardia provides update on near term milestones for CardiAMP, Helix
TipRanks · 09/23 13:20
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
Barchart · 09/23 08:15
Weekly Report: what happened at BCDA last week (0914-0918)?
Weekly Report · 09/21 09:49
Weekly Report: what happened at BCDA last week (0907-0911)?
Weekly Report · 09/14 09:52
BioCardia Highlights Therapeutic Pipeline at Investor Conference
TipRanks · 09/10 13:23
Weekly Report: what happened at BCDA last week (0831-0904)?
Weekly Report · 09/07 09:48
Weekly Report: what happened at BCDA last week (0824-0828)?
Weekly Report · 08/31 09:52
BioCardia: Advancing Regulatory Momentum in Helix Catheter and CardiAMP HF Programs Supports Buy Rating and Unchanged $25 Price Target
TipRanks · 08/24 15:55
BioCardia gets FDA confirmation of Helix meeting minutes
TipRanks · 08/24 13:00
BioCardia Advances Helix Catheter Toward De Novo Approval
TipRanks · 08/24 13:00
More
Webull provides a variety of real-time BCDA stock news. You can receive the latest news about Biocardia Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.